19 July 2021 | News
Medigen's COVID-19 vaccine is designed for use in adults aged 20 or older
image credit- shutterstock
The Food and Drug Administration of the Ministry of Health and Welfare in Taiwan has approved the manufacturing of Medigen’s COVID-19 vaccine.
Taiwan-based Medigen Vaccine Biologics Corp's (MVC) COVID-19 vaccine is designed for use in adults aged 20 or older, who will get two doses of the vaccine 28 days apart to build protection against COVID-19.
MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax plus aluminum hydroxide. The S-2P antigen is a trimeric and prefusion-stable recombinant spike protein developed by the U.S. NIH. MVC has obtained a global technology license for S-2P from the U.S. Vaccine Research Center at National Institutes of Health (NIH).
MVC established the production platform of MVC-COV1901 and based on MVC’s preclinical, Phase 1 and Phase 2 clinical study data, MVC-COV1901 has shown robust safety and promising immunogenicity responses.